Comparison of the Tamsulosin and Tolterodine Effectiveness in Stent-Related Symptoms Reduction Publisher



Mirsadeghi SA¹ ; Tamehri Zadeh SS¹ ; Fakhr Yasseri A¹ ; Tabibi A² ; Radfar MH¹ ; Taheri D³ Show Affiliations
Source: Translational Research in Urology Published:2021

Abstract

Introduction To compare the effectiveness of tamsulosin and Tolterodine in reducing stent-related symptoms with each other and with the control group we performed this randomized clinical trial. Methods 150 patients after successful first-time transurethral lithotripsy (TUL) for unilateral ureteral stones were elected for the study 17 patients were excluded in the first allocation. Other patients were randomized (With balanced blocked randomization) into three groups. In group 1, 41 patients received Tamsulosin (Omnic) 0.4mg once a day for a month and in group 2, 42 patients received tolterodine (Detrusitol) 2mg once a day for a month. In group 3, which was our control group, 50 patients received a placebo once a day for a month. Clinical stent-related symptoms questionnaires at the first visit (day 10) and before removing themes stent were completed. Two urine tests and an x-ray of the abdomen in the first visit have been performed. Results Despite the remarkable decrease in the severity of stent-related symptoms other than urine urgency in the control group (p-value<0.05), solitary use of neither tamsulosin nor tolterodine was superior to the control group, and also, they were not superior to each other with respect to improving double-J stent-related symptoms (p-value>0.05). Conclusions The results of our study show that administration of tolterodine and tamsulosin to reduce stent-related symptoms do not have superiority to each other and the control group. © 2021, Tehran University of Medical Sciences. All rights reserved.